Percutaneous Coronary Intervention with Everolimus-Eluting Versus Sirolimus-Eluting Stents in Diabetic Patients Presented with Acute Coronary Syndromes: A Short-term Comparative Clinical Outcome Study

Abstract

Background: The use of drug-eluting stents (DES) resulted in innovative progress in the field of interventional Cardiology. Nowadays, the most common indication for coronary stenting is acute coronary syndromes (ACS) due to the better clinical consequences of PCI compared with conservative management. However, in diabetic patients, there is a large debate in the literature regarding the selection of an optimal drug-eluting stent.
 Aim: This work aimed to compare short term clinical outcome post-percutaneous Coronary intervention with Everolimus-eluting stents (EES) versus Sirolimus-eluting stents (SES) in diabetic patients presented with ACS.
 Methods: The present study was carried out on 120 diabetic patients presented with acute coronary syndromes (Non-STEMI, Unstable angina) and divided into 2 groups; group 1 included patients treated with PCI with Everolimus eluting stenting (EES), and group 2 included patients treated with PCI with Sirolimus-eluting stenting (SES).
 Results: After 6 months of follow-up, the percentages of treated patients who were complicated with sudden cardiac death, congestive heart failure, and planned further PCI were 5%, 6.7%, and 6.7%, respectively in group 1, and were 3.3%, 8.3%, and 10% respectively in group 2. While no acute coronary syndrome or repeated coronary angiography was reported in both groups. In the current study, there was no statistically significant difference between the EES group and the SES group in diabetic patients either during implantation or during 6 months follow up (P-value >0.05).
 Conclusion: In this current study, both EES and SES are comparable to each other regarding the treatment of ACS in diabetic patients.